|Registry of biomedical companies:
   [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z] 581 active entries
Parque Tecnologico Bizkaia, Edif. 504
Phone: + 34 94 406 4525
Fax: + 34 94 406 4526
Please notice: This entry hasn't been updated by the submitting company for more than 2 years. It could be possible that this company doesn't longer exists.
Personalised monitoring and prediction of therapeutic response
Proteomika is a biotechnological corporation that was founded in 2002 belonging to the Progenika Group.
The company specialises in the development of diagnostic assays for complex diseases.
Proteomika's aim is to provide the medical community with tools for the non-invasive treatment and the individualised and personalised monitoring and prediction of the patient's response.
In the last few years, Progenika and Proteomika have developed in-house technology, such as DNA and protein chips for the diagnosis and prognosis of human disease.
Progenika's headquarters are located in the Bizkaia Technology Park, in the outskirts of Bilbao (Spain). Over 60 scientists work in state-of-the-art installations that have been specifically designed for the production and analysis of DNA chips as well as for the research and development of biomarkers for new assays.
Proteomika, alongside Progenika, aims to become a leader in the field of European "post-genomic" research through innovation and excellence.
Our mission is to develop, produce and commercialise novel and pioneering diagnostic products and services in the field of personalised medicine, using integral and efficient solutions.
Proteomika's aim is to become the international leader in the field of personalised medicine within the field of diagnosis and prognosis, based on their in-house research and development.
Last update of this entry: September 28, 2010